Introduction {#s0005}
============

Familial hypercholesterolemia (FH; MIM\# 143890) is an autosomal dominantly inherited disorder of cholesterol metabolism that affects approximately 1 in 500 individuals worldwide, thus corresponding to one of the most common mendelian disorders ([@bb0060]). FH is characterized by an excess of low-density lipoprotein cholesterol (LDL-c) in circulation, leading to deposits in peripheral tissues (xanthomas), and, more importantly, in the arterial wall, causing premature and accelerated atherosclerosis and an increased risk of coronary artery disease (CAD) at a young age ([@bb0020]). Defects in at least three different genes encoding for proteins involved in hepatic clearance of LDL-c from the plasma can cause FH. Mutations in the apolipoproteina B-100 (*APOB*) and in the proprotein convertase subtilisin/kexin 9 (*PCSK9*) genes can produce a phenotype of FH. The most frequently implicated gene, however, is the one encoding for the low-density lipoprotein receptor (*LDLR*). Mutations can occur all over the *LDLR* gene, but the majority of variants fall within the ligand-binding domain, which is encoded by exons 2 to 6 ([@bb0005]). Although the diagnostic algorithm of FH currently involves the screening of the *LDLR*, *APOB* and *PCSK9* genes, molecular studies have been showing that in a high number of clinically defined index-cases no pathogenic mutations can be identified at these three loci. In the study of [@bb0105], for example, 41% of the index-cases could not be molecularly diagnosed; this percentage was around 50% in the study of [@bb0015]. On the other hand, the role of some genetic variants described in the previously referred loci (*LDLR*, *APOB* and *PCSK9*), remains to be established ([@bb0115]). Synonymous variants, for example, although previously dismissed as "non-pathogenic", are increasingly recognized as being associated with clinically relevant phenotypes. In FH their potential to modulate splicing efficiency through the alteration of exon splicing enhancers has been demonstrated ([@bb0015], [@bb0025], [@bb0140]). Portugal, in contrast to most of the other Southern European countries, has a high mortality rate due to CAD, which represents the second cause of death in the country ([@bb9000]). In the Portuguese Azores Islands the death rate from CAD is two-fold higher than in mainland Portugal ([@bb0040]). A previous study using apparently healthy Azorean subjects showed a high prevalence of dyslipidemia in this population ([@bb0010]). Because FH is one of the risk factors of CAD, the molecular characterization of 10 Azorean index-cases with possible FH was performed by analyzing the *LDLR*, *APOB* and *PCSK9* loci, using a DNA array (LIPOchip) and subsequently sequencing the full *LDLR* gene. An adult possible FH case characterized according to the Simon Broome Heart Research Trust criteria is an individual with total cholesterol (TC) over 290 mg/dl and/or LDL cholesterol (LDL-c) over 190 mg/dl, and with family history of myocardial infarction or high level cholesterol (adapted from the [@bb0130]. To further clarify the role of some genetic variants detected in the *LDLR* gene, we additionally sequenced exons 2 to 6 and the corresponding exon/intron boundaries in a series of 23 index-cases of possible FH.

Subjects and methods {#s0015}
--------------------

At two regional health centers (Vila Franca and Nordeste), blood samples were collected after informed consent from 33 unrelated index-cases, 23 women (69.7%) and 10 men (30.3%) born in the Azores and of Azorean ancestry. The individuals selected fulfilled the criteria of "possible FH", according to the [@bb0130]. Secondary causes of hypercholesterolemia, such as diabetes, hypothyroidism and nephrotic syndrome, were considered exclusion criteria. TC was determined for all subjects in collaborating laboratories, using standardized protocols. LDL-c concentration was calculated by the Friedewald formula ([@bb0055]). DNA was extracted using the salting-out method ([@bb0095]). From the 33 individuals collected, 10 (7 women and 3 men) who presented high levels of TC and whose samples simultaneously fulfilled the necessary DNA purity and concentration requirements were selected for microarray analysis. Genotyping was performed using the LIPOchip® Array version 7 (Progenika, Derio, Spain) ([@bb0135]). This platform includes a microarray for the detection of point mutations and small insertions/deletions (indels) as well as copy number variations in the *LDLR* gene. All exons of the *LDLR* gene were analyzed; the array included the analysis of 207 point mutations in the gene *LDLR*, 4 mutations in the gene *APOB* and seven in the gene *PCSK9* (information provided by Progenica). The chip further detects point mutations in exon 26 of the *APOB* gene as well as a few mutations in the *PCSK9* gene ([@bb0110]). Whenever the LIPOchip® Array fails to identify mutations a second step is carried out by sequencing the promoter, the translated exon sequences, and the exon--intron boundaries of the 18 exons of the *LDLR* gene ([@bb0110]). For the remaining 23 index-cases, exons 2 to 6, which define the ligand-binding domain of the *LDLR* gene, were sequenced. Primers were designed to flank the entire coding region and the intron--exon junctions of each exon. All primer sequences, annealing temperatures, as well as expected PCR products are available upon request. Sequencing of purified PCR products was performed using the BigDye Terminator v3.1 sequencing kit (Applied Biosystems) following the manufacturer\'s protocols and sequences were run in an ABI 310 sequencer (Applied Biosystems).

Haplotypic analyses for the six synonymous variants associated with cholesterol levels were performed using the Arlequin3.11 software package ([@bb0045]). Allelic frequencies at population level were obtained for comparative purposes from dbSNP (NCBI) using the 1000 Genomes as a source.

To infer the putative effects of a missense alteration identified (c.185C \> T; p.Thr62Met) several analyses were performed. The amino acid conservation index (CI), defined as the percentage of species from the NCBI list that have the wild-type amino acid in a given position, was estimated for position 62 of the LDLR protein. A total of 39 amino acid reference sequences of different mammal species were used for amino acid CI calculation. Sequences were aligned using Muscle v3.6 ([@bb0030]). The pathogenicity of the c.185C \> T variant was further studied using the software packages "Mutation Taster" ([@bb0125]) and "MutPred" ([@bb0065]).

Results and discussion {#s0010}
======================

Mutation screening (*LDLR*, *APOB* and *PCSK9*) of 10 index-cases of possible FH {#s0020}
--------------------------------------------------------------------------------

In the 10 unrelated "possible FH" cases analyzed using the LIPOchip® Array, no mutations were detected. The sequencing of the promoter and the 18 exons of the *LDLR* gene in these individuals revealed the presence of eighteen variants, corresponding to two missense alterations and sixteen synonymous variants ([Table 1](#t0005){ref-type="table"}). The sample analyzed therefore contains a high number of variants when compared with samples used in similar studies, such as the one by [@bb0115]; this latter study, which screened the whole *LDLR* gene in 17 samples of Pakistani origin, described only two synonymous variants (also detected in the present sample). This indication of high genetic diversity of the Azores is not all together surprising, since previous research conducted in the Azorean populations, using different genetic systems, has shown considerable levels of diversity ([@bb0100], [@bb0120]). In one of the 10 individuals analyzed two missense alterations, both in the heterozygous state, were detected ([Table 1](#t0005){ref-type="table"}). On what concerns the missense alteration identified at exon 5 (c.806G \> A, rs143992984), in silico analysis of this variant predicts that given the high levels of nucleotide and amino acid conservation, it should be pathogenic ([@bb0035]). However, segregation analysis of this variant in a Portuguese family failed to prove its association with the FH phenotype ([@bb0015]). Furthermore, functional validation indicates that this alteration does not impair lipoprotein-binding capacity, and therefore should be classified as non-pathogenic ([@bb0035]). The other missense alteration identified at exon 8 (c.1171G \> A, rs11669576) has been classified as non-pathogenic ([www.ucl.ac.uk/ldlr/LOVDv.1.1.0](http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0){#ir0015}) and is rare in the Portuguese mainland population (data not shown).

Six out of the sixteen synonymous variants identified in the present study ([Table 1](#t0005){ref-type="table"}), which have been consistently confirmed in several studies as being associated with alterations in cholesterol levels ([@bb0070], [@bb0075], [@bb0090]), are described in detail in [Table 2](#t0010){ref-type="table"}. When compared with the normal population, a higher frequency of the risk alleles was observed in the 10 index-cases of possible FH ([Table 2](#t0010){ref-type="table"}). Concerning 2 synonymous variants related to low LDL-c levels the T variant at c.81C \> T, rs2228671 was found in the heterozygous state in 4 subjects (40%). This allele reaches a frequency of approximately 6% in Europe and appears to have the strongest association with LDL-c levels across multiple European populations, each copy being related to a decrease of LDL-c levels and to a significantly lower risk of coronary artery disease ([@bb0070]). By the other hand, the T allele of the synonymous variant c.1617C \> T, rs5929 is very rare in populations of European ancestry ([@bb0090]). Noteworthy, the T allele is present in one of the 10 index-cases analyzed (10%); this variant displays its higher percentage in African populations such as the Yoruba in Nigeria (12.3%) and the Masai in Kenya (13.5%); a strong association of this allele with a protective role concerning LDL-c levels in multi generational families of African descent has been described ([@bb0090]). The presence of an allele typical of African populations in the analyzed sample could be justified by the Azorean population genetic background. In fact, both historical and genetic data support a sub-Saharan African contribution to the peopling of the Azores ([@bb0080], [@bb0085]).

In the total of 10 index-cases analyzed seven different haplotypes for the six synonymous variants associated with cholesterol levels ([Table 2](#t0010){ref-type="table"}) were present (data not shown). The most frequent haplotype is TTCGCC (45%), which is a "risk" haplotype, being formed exclusively by risk alleles. This haplotype is present in 3 subjects (2, 5 and 8).

Analysis of exons 2 to 6 of the *LDLR* gene in an additional series of 23 possible FH index-cases {#s0025}
-------------------------------------------------------------------------------------------------

To add information as to the role of the variants detected in the initial 10 index-cases, 23 additional cases of possible FH were also studied. For these samples, demographic and lipid profile data are presented in [Table 3](#t0015){ref-type="table"}. The sequencing of exons 2 to 6 of the *LDLR* gene of these 23 cases allowed the identification of four variants ([Table 1](#t0005){ref-type="table"}): two of these were missense alterations, both transitions and in a heterozygous state; the 2 remaining alterations correspond to synonymous variants. The missense alteration c.806G \> A, rs143992984 was already found in the mutation screening of the 10 index-cases of possible FH ([Table 1](#t0005){ref-type="table"}). Concerning the missense alteration c.185C \> T, identified in one individual, is reported in the British Heart Foundation database ([www.ucl.ac.uk/ldlr/LOVDv.1.1.0](http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0){#ir0020}) for Caucasians populations, but is novel for the Portuguese population (data not shown). No functional studies have been performed for this alteration ([@bb0050]), whose in silico analysis predicts not to be pathogenic. The amino acid CI estimated for position 62 of the LDLR protein across the protein reference sequences of the class Mammals that is 89.7%, suggesting it to be a highly stable position. Because in silico analysis of this variant failed to produce conclusive results, and since segregation studies were impossible to perform, the association of this variant with the phenotype remains to be established.

In exon 2 two synonymous variations were also detected ([Table 1](#t0005){ref-type="table"}). The variant c.81C \> T, rs2228671 was detected in 10 individuals, and is frequent in the Portuguese mainland population (data not shown); on the other hand the c.90C \> T variant, identified in one individual of our sample is also being described for the first time for the Portuguese population (data not shown). [Fig. 1](#f0005){ref-type="fig"} shows 4 pedigrees of cases included in our sample, as illustrative of the types of dyslipidemia present in these "possible cases". These pedigrees show an autosomal dominant pattern of inheritance, characteristic of FH.

Although no pathogenic mutations were found in the studied population, several genetic alterations were detected, allowing the establishment of a FH variant profile in the Azores. This profile deserves further investigation, since data derived will promote the early detection of this disease and the minimization of its impact.
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###### 

Genetic variants obtained after *LDLR* gene sequencing in a total of 33 possible HF cases, grouped by type of variation and set of individuals used in this study.

  *LDLR* gene sequencing                                                                    
  --------------------------- ----------- ------------- -------------------------- -------- --------------
  *Missense variants*                                                                       
  c.806G \> A; p.Gly269Asp    Exon 5      rs143992984   c.185C \> T; p.Thr62Met    Exon 2   No reference
  c.1171G \> A;p.Ala391Thr    Exon 8      rs11669576    c.806G \> A; p.Gly269Asp   Exon 5   rs143992984
                                                                                            
  *Synonymous variants*                                                                     
  c.81C \> T; p.Cys27Cys      Exon 2      rs2228671     c.81C \> T; p.Cys27Cys     Exon 2   rs2228671
  c.1060 + 7 T \> C           Intron 7    rs2738442     c.90C \> T; p.Asn30Asn     Exon 2   No reference
  c.1060 + 10G \> C           Intron 7    rs12710260                                        
  c.1359-30C \> T             Intron 9    rs1003723                                         
  c.1413A \> G; p.Arg471Arg   Exon 10     rs5930                                            
  c.1617C \> T; p.Pro539Pro   Exon 11     rs5929                                            
  c.1706-55A \> C             Intron 11   rs2738447                                         
  c.1706-69G \> T             Intron 11   rs7259278                                         
  c.1725C \> T; p.Leu575Leu   Exon 12     rs1799898                                         
  c.1773C \> T; p.Asn591Asn   Exon 12     rs688                                             
  c.1959 T \> C;p.Val653Val   Exon 13     rs5925                                            
  c.2232A \> G; p.Arg744Arg   Exon 15     rs5927                                            
  c.2389 + 46C \> T           Intron 16   rs2738460                                         
  c.2548-80G \> A             Intron 18   rs2116897                                         
  c.2548-42A \> G             Intron 18   rs6413504                                         
  c.\* + 52G \> A             Intron 18   rs14158                                           

Official name following rules of human genome variation society (HGVS).

SNP identification in NCBI-SNP database.

###### 

Demographic, lipid profile and genetic variants in *LDLR* gene previously associated with LDL-c levels for each of ten individuals with possible HF analysed in LipoCHIP array. Data in bold are the alleles which are associated with altered cholesterol levels.

                                 Variants previously associated with LDL-c levels                                                                                   
  ------------------------------ -------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  **1**                          62                                                 F         293       204       C/**T**   C/C       T/T       A/A       C/**T**   C/C
  **2**                          48                                                 F         333       189       **T/T**   **T/T**   **C/C**   **G/G**   C/C       C/C
  **3**                          52                                                 F         281       208       **T/T**   C/**T**   T/**C**   A/**G**   C/**T**   C/C
  **4**                          55                                                 M         298       219       C/C       C/C       T/T       A/A       C/C       C/**T**
  **5**                          27                                                 M         268       198       **T/T**   **T/T**   **C/C**   **G/G**   C/C       C/C
  **6**                          54                                                 F         317       170       C/C       C/C       T/T       A/A       C/**T**   C/C
  **7**                          50                                                 F         299       155       **T/T**   C/**T**   T/**C**   **G/G**   C/C       C/C
  **8**                          43                                                 F         295       175       **T/T**   **T/T**   **C/C**   **G/G**   C/C       C/C
  **9**                          75                                                 F         292       214       C/**T**   C/**T**   T/**C**   A/**G**   C/**T**   C/C
  **10**                         69                                                 M         280       205       C/C       C/C       T/T       A/**G**   C/C       C/C
  Minor allele frequency (MAF)   1000 genomes                                       28%       28%       33%       36%       6%        12%                           
  **Present study**              **60%**                                            **45%**   **45%**   **55%**   **20%**   **5%**                                  
                                 Ancestral allele                                   C         C         T         A         T         C                             

Total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c).

###### 

Demographic and lipid profile data for each of 23 individuals selected for the analysis of exons 2 to 6 of the *LDLR* gene.

  Sample ID   Age   Gender   TC    LDL-c
  ----------- ----- -------- ----- -------
  11          57    F        293   201
  12          58    F        329   238
  13          26    F        352   266
  14          52    F        290   214
  15          56    M        266   192
  16          71    M        297   186
  17          54    M        269   194
  18          41    F        280   207
  19          60    F        269   194
  20          63    F        278   207
  21          58    F        305   211
  22          34    F        300   209
  23          54    M        311   225
  24          49    M        300   150
  25          44    M        265   191
  26          53    M        287   193
  27          51    F        322   233
  28          46    F        285   193
  29          53    F        320   221
  30          47    F        265   195
  31          56    F        277   195
  32          21    F        307   176
  33          44    F        280   205

Total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-c) levels are represented as mg/dl. M = male and F = female.
